These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 35285672)

  • 21. In vivo effects of recombinant human DNase I on sputum in patients with cystic fibrosis.
    Shah PL; Scott SF; Knight RA; Marriott C; Ranasinha C; Hodson ME
    Thorax; 1996 Feb; 51(2):119-25. PubMed ID: 8711640
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase 3 randomized study of the efficacy and safety of inhaled dry powder mannitol for the symptomatic treatment of non-cystic fibrosis bronchiectasis.
    Bilton D; Daviskas E; Anderson SD; Kolbe J; King G; Stirling RG; Thompson BR; Milne D; Charlton B;
    Chest; 2013 Jul; 144(1):215-225. PubMed ID: 23429964
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The clinical presentations of pulmonary aspergillosis in children with cystic fibrosis - preliminary report.
    Walicka-Serzysko K; Sands D
    Dev Period Med; 2015; 19(1):66-79. PubMed ID: 26003072
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost Effectiveness of Inhaled Mannitol (Bronchitol
    Warren E; Morgan K; Toward TJ; Schwenkglenks M; Leadbetter J
    Pharmacoeconomics; 2019 Mar; 37(3):435-446. PubMed ID: 30666534
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Retrospective review of the effects of rhDNase in children with cystic fibrosis.
    Davies J; Trindade MT; Wallis C; Rosenthal M; Crawford O; Bush A
    Pediatr Pulmonol; 1997 Apr; 23(4):243-8. PubMed ID: 9141109
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of rhDNase on airflow obstruction and mucociliary clearance in cystic fibrosis.
    Laube BL; Auci RM; Shields DE; Christiansen DH; Lucas MK; Fuchs HJ; Rosenstein BJ
    Am J Respir Crit Care Med; 1996 Feb; 153(2):752-60. PubMed ID: 8564129
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhaled mannitol improves lung function in cystic fibrosis.
    Jaques A; Daviskas E; Turton JA; McKay K; Cooper P; Stirling RG; Robertson CF; Bye PTP; LeSouëf PN; Shadbolt B; Anderson SD; Charlton B
    Chest; 2008 Jun; 133(6):1388-1396. PubMed ID: 18339790
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhaled mannitol in patients with cystic fibrosis: A randomised open-label dose response trial.
    Teper A; Jaques A; Charlton B
    J Cyst Fibros; 2011 Jan; 10(1):1-8. PubMed ID: 20888307
    [TBL] [Abstract][Full Text] [Related]  

  • 29. No positive effect of rhdnase on the pulmonary colonization in children with cystic fibrosis.
    Bonestroo HJ; Slieker MG; Arets HG
    Monaldi Arch Chest Dis; 2010 Mar; 73(1):12-7. PubMed ID: 20499789
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aerosolized recombinant human DNase I for the treatment of cystic fibrosis.
    Shak S
    Chest; 1995 Feb; 107(2 Suppl):65S-70S. PubMed ID: 7842816
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis.
    Eng PA; Morton J; Douglass JA; Riedler J; Wilson J; Robertson CF
    Pediatr Pulmonol; 1996 Feb; 21(2):77-83. PubMed ID: 8882210
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of a short course of rhDNase on cough and mucociliary clearance in patients with cystic fibrosis.
    Robinson M; Hemming AL; Moriarty C; Eberl S; Bye PT
    Pediatr Pulmonol; 2000 Jul; 30(1):16-24. PubMed ID: 10862158
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tobramycin inhalation powder manufactured by improved process in cystic fibrosis: the randomized EDIT trial.
    Galeva I; Konstan MW; Higgins M; Angyalosi G; Brockhaus F; Piggott S; Thomas K; Chuchalin AG
    Curr Med Res Opin; 2013 Aug; 29(8):947-56. PubMed ID: 23672633
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multicenter, open-label study of recombinant human DNase in cystic fibrosis patients with moderate lung disease. DNase International Study Group.
    Harms HK; Matouk E; Tournier G; von der Hardt H; Weller PH; Romano L; Heijerman HG; FitzGerald MX; Richard D; Strandvik B; Kolbe J; Kraemer R; Michalsen H
    Pediatr Pulmonol; 1998 Sep; 26(3):155-61. PubMed ID: 9773909
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term safety of tobramycin inhalation powder in patients with cystic fibrosis: phase IV (ETOILES) study.
    Sommerwerck U; Virella-Lowell I; Angyalosi G; Viegas A; Cao W; Debonnett L
    Curr Med Res Opin; 2016 Nov; 32(11):1789-1795. PubMed ID: 27435882
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhaled mannitol and cystic fibrosis. Unnecessary bronchial irritation.
    Prescrire Int; 2014 Apr; 23(148):89-91. PubMed ID: 24860889
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recombinant human DNase (rhDNase) influences phospholipid composition, surface activity, rheology and consecutively clearance indices of cystic fibrosis sputum.
    Griese M; App EM; Duroux A; Burkert A; Schams A
    Pulm Pharmacol Ther; 1997; 10(1):21-7. PubMed ID: 9344829
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhaled mannitol in the treatment of non-cystic fibrosis bronchiectasis in adults.
    Gjoerup J; Hilberg O; Bendstrup E
    Respirology; 2012 Aug; 17(6):927-32. PubMed ID: 22564014
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis.
    Ramsey BW; Astley SJ; Aitken ML; Burke W; Colin AA; Dorkin HL; Eisenberg JD; Gibson RL; Harwood IR; Schidlow DV
    Am Rev Respir Dis; 1993 Jul; 148(1):145-51. PubMed ID: 8317790
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Beneficial effect of inhaled mannitol and cough in asthmatics with mucociliary dysfunction.
    Daviskas E; Anderson SD; Eberl S; Young IH
    Respir Med; 2010 Nov; 104(11):1645-53. PubMed ID: 20576419
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.